Company intelligence / Profile preview

Lipidica

Ownership: Private
Development stage: Other

Overview

Lipidica has developed a non-invasive blood-based diagnostic test for early detection of pancreatic cancer and potentially other malignancies. The technology is based on patented methods for analyzing the blood lipidome, supported by AI-driven data interpretation. The company is currently conducting clinical studies to validate the performance of its LDPC test, which has shown promising accuracy in early research and publications including Nature Communications.

Therapeutic areas: Oncology
Modalities: Diagnostic testLaboratory-based lipidomic analysis
Industry: Metabolite Diagnostics

Partnerships

University of PardubiceFONS JK Group

Beyond the preview

Go deeper on Lipidica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipidica.

Explore the full profile